Effects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamine

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Bacon, David J ^a   Tang, Doug ^b   Salas, Carola ^a   Roncal, Norma ^c   Lucas, Carmen ^a   Gerena, Lucia ^c   Tapia, Lorena ^a   Llanos Cuentas, A Alejandro ^d   Garcia, Coralith ^d   Solari, Lelv ^d   Kyle, Dennis ^e   Magill, Alan J ^c  

^a California   (Peru)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROPTERATE SYNTHASE; FANSIDAR; MICROBIAL ENZYME; SYNTHETASE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; DIHYDROPTEROATE SYNTHASE; PYRIMETHAMINE; SULFADOXINE;

ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PERU; PLASMODIUM FALCIPARUM; POINT MUTATION; SINGLE DRUG DOSE; TREATMENT RESPONSE; WILD TYPE; ANIMAL; DRUG EFFECT; ENZYMOLOGY; GENETICS;

PLASMODIUM FALCIPARUM;

ANIMALS; ANTIMALARIALS; DIHYDROPTEROATE SYNTHASE; PLASMODIUM FALCIPARUM; POINT MUTATION; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 69849100056     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006762     Document Type: Article

References (52)

1. Gebru-Woldearegai T, Hailu A, Grobusch MP, Kun JFJ (2005) Molecular surveillance of mutations in dihydrofolate reductase and dihyropteroate synthase genes of Plasmodium falciparum in Ethiopia. Am J Trop Med Hyg 73: 1131-1134.
2. Schonfeld M, Barreto Miranda I, Schunk M, Maduhu I, Maboko L, et al. (2007) Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Malar J 6: 2.
3. Sendagire H, Kaddumukasa M, Ndagire D, Aguttu C, Nassejje M, et al. (2005) Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative. Acta Tropica 95: 172-182.
4. Marquino W, MacArthur JR, Barat LM, Oblitas FE, Arrunategui M, et al. (2003) Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria on the north coast of Peru. Am J Trop Med Hyg 68: 120-123.
5. Cortese JF, Caraballo A, Contreras CE, Plowe CV (2002) Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186: 999-1006 Epub 2002 Sep 1009.
6. Le Bras J, Durand R (2003) The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam Clin Pharmacol 17(2): 147-153.
7. Nirmalan N, Sims PF, Hyde JE (2004) Translational up-regulation of antifolate drug targets in the human malaria parasite Plasmodium falciparum upon challenge with inhibitors. Mol Biochem Parasitol 136: 63-70.
8. Zhang K, Rathod PK (2002) Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science 296: 545-547.
9. Nzila A, Ward SA, Marsh K, Sims PF, Hyde JE (2005) Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. Trends Parasitol 21: 292-298.
10. Kublin JG, Witzig RS, Shankar AH, Zurita JQ, Gilman RH, et al. (1998) Molecular assays for surveillance of antifolate-resistant malaria. Lancet 351: 1629-1630.
11. Cortese JF, Plowe CV (1998) Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Molecular and Biochemical Parasitology 94: 205-214.
12. Dunyo S, Ord R, Hallett R, Jawara M, Walraven G, et al. (2006) Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clin Trials 1: e14.
13. Hallett RL, Dunyo S, Ord R, Jawara M, Pinder M, et al. (2006) Chloroquine/sulphadoxine-pyrimethamine for gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials 1: e15.
14. Mbugi EV, Mutayoba BM, Malisa AL, Balthazary ST, Nyambo TB, et al. (2006) Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. Malar J 5: 94.
15. Nzila A, Ochong E, Nduati E, Gilbert K, Winstanley P, et al. (2005) Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Transactions of the Royal Society of Tropical Medicine and Hygiene 99: 341-346.
16. Djaman JA, Mazabraud A, Basco L (2007) Sulfadoxine-pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Cote d'Ivoire. Ann Trop Med Parasitol 101: 103-112.
17. Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, et al. (2007) Assessment and Continued Validation of the Malaria SYBR Green I-Based Fluorescence Assay for Use in Malaria Drug Screening. Antimicrob Agents Chemother 51: 1926-1933.
18. Enevold A, Nkya WM, Theisen M, Vestergaard LS, Jensen AT, et al. (2007) Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malar J 6: 153.
19. Francis D, Nsobya SL, Talisuna A, Yeka A, Kamya MR, et al. (2006) Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis 193: 978-986.
20. Lee SA, Yeka A, Nsobya SL, Dokomajilar C, Rosenthal PJ, et al. (2006) Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda. J Infect Dis 193: 1160-1163.
21. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, et al. (2006) Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 80: 582-596.
22. Magill AJ, Zegarra J, Garcia C, Marquino W, Ruebush TK 2nd (2004) Efficacy of sulfadoxine-pyrimethamine and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon basin of Peru. Rev Soc Bras Med Trop 37: 279-281.
23. Organization WH (1973) Chemotherapy of malaria and resistance to antimalarials: report of a WHO Scientific Working Group. World Health Organ Tech Rep Ser 529: 30-35.
24. Organization WH (2003) Assesment and monitoring of anitmalarial drug efficacy for the treatment of uncomplicated falaciparum malaria: Geneva: WHO/UNICEF.
25. Mendez F, Munoz A, Plowe CV (2006) Use of area under the curve to characterize transmission potential after antimalarial treatment. Am J Trop Med Hyg 75: 640-644.
26. Ayala E, Lescano AG, Gilman RH, Calderon M, Pinedo VV, et al. (2006) Polymerase chain reaction and molecular genotyping to monitor parasitological response to anti-malarial chemotherapy in the Peruvian Amazon. Am J Trop Med Hyg 74: 546-553.
27. Chenet SM, Branch OH, Escalante AA, Lucas CM, Bacon DJ (2008) Genetic diversity of vaccine candidate antigens in Plasmodium falciparum isolates from the Amazon basin of Peru. Malar J 7: 93.
28. Juliano JJ, Trottman P, Mwapasa V, Meshnick SR (2008) Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay. Am J Trop Med Hyg 78: 892-894.
29. Green MD, Bergqvist Y, Mount DL, Corbett S, D'Souza MJ (1999) Improved validated assay for the determination of mefloquine and its carboxy metabolite in plasma, serum and whole blood using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 727: 159-165.
30. Mockenhaupt FP, Bousema JT, Eggelte TA, Ehrhardt S, Otchwemah RN, et al. (2005) Concurrence of Plasmodium falciparum dhfr and crt mutations in northern Ghana. Malar J 4: 42.
31. Nsimba B, Jafari-Guemouri S, Malonga DA, Mouata AM, Kiori J, et al. (2005) Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. Tropical Medicine & International Health 10: 1030-1037.
32. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, et al. (1997) Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176: 1590-1596.
33. Berzosa PJ, Puente S, Benito A (2005) Malaria cure with sulphadoxine/ pyrimethamine combination in 12 semi-immune adults from West-Central Africa with high rates of point mutations in Plasmodium falciparum dhfr and dhps genes. Parasitol Res 97: 287-289.
34. Ndiaye D, Daily JP, Sarr O, Ndir O, Gaye O, et al. (2005) Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Trop Med Int Health 10: 1176-1179.
35. Noranate N, Durand R, Tall A, Marrama L, Spiegel A, et al. (2007) Rapid Dissemination of Plasmodium falciparum Drug Resistance Despite Strictly Controlled Antimalarial Use. PLoS ONE 2: e139.
36. Roper C, Pearce R, Nair S, Sharp B, Nosten F, et al. (2004) Intercontinental Spread of Pyrimethamine-Resistant Malaria. Science 305: 1124-.
37. Pearce R, Malisa A, Kachur SP, Barnes K, Sharp B, et al. (2005) Reduced variation around drug-resistant dhfr alleles in African Plasmodium falciparum. Mol Biol Evol 22: 1834-1844.
38. Durand S, Marquino W, Cabezas C, Utz G, Fiestas V, et al. (2007) Unusual pattern of Plasmodium falciparum drug resistance in the northwestern Peruvian Amazon region. Am J Trop Med Hyg 76: 614-618.
39. Mendez F, Munoz A, Carrasquilla G, Jurado D, Arevalo-Herrera M, et al. (2002) Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol 156: 230-238.
40. Sutherland CJ, Alloueche A, Curtis J, Drakeley CJ, Ord R, et al. (2002) Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg 67: 578-585.
41. Basco LK (2003) Molecular epidemiology of malaria in Cameroon. XVI. Longitudinal surveillance of in vitro pyrimethamine resistance in Plasmodium falciparum. Am J Trop Med Hyg 69: 174-178.
42. Basco LK, Ringwald P (1999) Molecular epidemiology of malaria in Yaounde, Cameroon IV. Evolution of pyrimethamine resistance between 1994 and 1998. Am J Trop Med Hyg 61: 802-806.
43. Marquino W, Huilca M, Calampa C, Falconi E, Cabezas C, et al. (2003) Efficacy of mefloquine and a mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru. Am J Trop Med Hyg 68: 608-612.
44. Hoffman IF, Jere CS, Taylor TE, Munthali P, Dyer JR, et al. (1999) The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. Aids 13: 487-494.
45. Trager W, Jenson JB (1978) Cultivation of malarial parasites. Nature 273: 621-622.
46. Oduola AM, Milhous WK, Salako LA, Walker O, Desjardins RE (1987) Reduced in-vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum. Lancet 2: 1304-1305.
47. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD (1979) Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16: 710-718.
48. Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE (1985) In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob Agents Chemother 27: 525-530.
49. Berenbaum MC (1978) A method for testing for synergy with any number of agents. J Infect Dis 137: 122-130.
50. Pattanapanyasat K, Kotipun K, Yongvanitchit K, Hider RC, Kyle DE, et al. (2001) Effects of hydroxypyridinone iron chelators in combination with antimalarial drugs on the in vitro growth of Plasmodium falciparum. Southeast Asian J Trop Med Public Health 32: 64-69.
51. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE (1995) Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52: 565-568.
52. Vasconcelos KF, Plowe CV, Fontes CJ, Kyle D, Wirth DF, et al. (2000) Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Mem Inst Oswaldo Cruz 95: 721-728.